The power of a central lab at the touch of a button.

The FDA-cleared, CLIA-Waived, binx io platform uses ultra-rapid polymerase chain reaction (PCR) amplification in conjunction with our proprietary electrochemical detection to achieve sensitivity and specificity on par with central lab performance.

» Contact Us

Easy-to-use platform requires no calibration, preventative maintenance, or interpretation of results and can be used by non-lab-trained personnel.

~30-minute PCR testing with sensitivity and specificity on par with central lab tests.

Improve your patient experience and administer treatment before your patients leave the clinic.

Decrease the risk of infection spread with asymptomatic and symptomatic testing for males and females.

Additional revenue stream for your clinic or hospital with established CPT reimbursement codes: 87491, 87591, or 87801.

How it works.

Learn how the binx io is transforming diagnostics with rapid results at the point-of-care

Clinically-Proven, FDA-Cleared

Clinical performance measured against three FDA-cleared standard-of-care molecular platforms

TARGET FEMALE MALE
SENSITIVITY SPECIFICITY SENSITIVITY SPECIFICITY
Chlamydia 96.1% 99.1% 92.5% 99.3%
Gonorrhea 100.0% 99.9% 97.3% 100.0%

2,445 person (1,523 females; 992 males) multi-center clinical study. As published in JAMA Network Open.

Downloads

Together we can help stop the spread

Sexually transmitted infections (STIs) are on the rise and testing pathways are struggling to keep up..

Traditional_Pathway

Traditional pathway

Sample sent to central reference laboratory

Test results available

1-10 days

Treatment may be inappropriate before leaving the clinic or patients may be lost to follow up

binx_io_pathway

binx io pathway

Sample run on binx io point-of-care test

Test results available

~30 mins

Increases treatment compliance with same visit test and treatment